NCT00031317 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Apfeldorf WJ, Spielman LA, Cloitre M, Heckelman L, Shear MK
Morbidity of comorbid psychiatric diagnoses in the clinical presentation of panic disorder. Depress Anxiety. 2000;12(2):78-84.
Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan;155(1):36-42.
Black DW, Wesner R, Bowers W, Gabel J
A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993 Jan;50(1):44-50.

Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression

Details for clinical trial NCT00031317

Clinical trial NCT00031317 - References